Manufacturer: U.S. Made Peptides
Pharmaceutical name: Epithalamin
Pack: 1 vial (50 mg)
Epithalon is a synthetic form of the tetra-peptide known as Epithalamin (epithalon tetra), which is naturally generated by the pineal gland in the brain. This tetra-peptide consists of four amino acids (alanine, glutamic acid, aspartic acid, and glycine) and has been demonstrated to have a variety of positive biological effects in both animal and human research. Prolonged exposure to Epithalamin has been linked to an increase in both the average and maximum lifespans of aging rats, mice, and flies. In human cells, Epithalon enhances the enzymatic activity of telomerase, leading to the elongation of telomeres, potentially due to the reactivation of the telomerase gene. Telomerase works to lengthen human DNA, effectively making cells biologically younger, thereby allowing for the potential extension of the lifespan of a cell population and the body as a whole. Results from a year-long study involving patients with accelerated aging who were treated with Epithalon indicated that the peptide normalized metabolism and improved the condition of various metabolic systems.
The peptide was also found to lower serum insulin and fatty acid levels in rabbits while enhancing glucose tolerance in these animals. Additionally, Epithalon stimulates the immune system by increasing the count of antibody-producing cells that combat infections. As a powerful antioxidant, Epithalon promotes the production of numerous antioxidant enzymes within the body, thus bolstering antioxidant defense. Overall, findings suggest a high effectiveness of Epithalamin therapy in mitigating age-related illnesses, including several types of cancer, metabolic syndromes, and heart diseases. These studies illustrate the peptide's potential to decelerate disease progression and lengthen human lifespan.
Epithalon should be administered subcutaneously or intramuscularly for optimal effectiveness, as it is degraded when taken orally. A dosage of 5 mg of Epithalon can be injected once or twice daily, preferably in the morning and afternoon if administered twice. The injections can be given over a period of 20 days, followed by a break of four to six months between cycles. Once Epithalon is reconstituted in BAC water, it remains stable for the full 20-day treatment period if kept at 4-8°C. After this period, the Epithalon will diminish in potency and should be discarded.
Long-term clinical trials on humans have reported no adverse effects associated with Epithalon. In these trials, the peptide was administered every three days at a dosage of 10 mg in 2 ml of saline by intramuscular injection, with intervals of six months between treatment courses.